Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$117M+0.4% YoY

Gross Profit

$117M99.7% margin

Operating Income

$57M48.3% margin

Net Income

$41M35.3% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

+12.9%

Cash Flow

Operating Cash Flow

$65M

Free Cash Flow

$64M

Stock-Based Comp.

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$521M

Stockholders' Equity

$606M

Cash & Equivalents

$620M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$117M	+0.4%
Gross Profit	$117M	$116M	+0.9%
Operating Income	$57M	$51M	+10.1%
Net Income	$41M	$43M	-4.2%

Revenue Segments

Collaborative arrangements revenue

$117M99%

Collaborative arrangement, co-promotion agreements

$676,0001%

Collaborative arrangement, other agreements

$396,0000%

Sale of active pharmaceutical ingredient

$144,0000%

Collaborative arrangement, collaboration and license agreements

$114,0000%

Geographic Segments

Canada and Mexico

$800,00035%

North America

$765,00034%

Europe and Other

$702,00031%